What is PNC-27?
PNC-27 is a 32-amino-acid synthetic peptide. It joins amino acids 12 to 26 of the tumour-suppressor protein p53, the region that binds the protein HDM-2 (also called MDM2), to a membrane-penetrating leader sequence. It was developed by Matthew Pincus and colleagues, who reported in laboratory studies that it binds HDM-2 in the membranes of cancer cells and damages those cells, while sparing normal cells (Kanovsky et al., PNAS, 2001, and later papers).
PNC-27 product specifications
- Compound: PNC-27
- Structure: p53 residues 12-26 linked to a membrane-penetrating sequence (32 amino acids in total)
- Vial sizes: 5mg and 10mg
Regulatory status
PNC-27 is not an approved medicine in the US, UK, EU or Canada and has not completed human clinical trials. It is not a cancer treatment. This product is sold for laboratory research use only.
Related research peptides
- FOXO4-DRI is another peptide designed to disrupt a p53 protein interaction.
Available sizes: 5mg and 10mg
PNC-27 is offered in two vial sizes: 5mg and 10mg. Both contain the same peptide. The figure is the total amount of peptide in the vial, supplied as a dry (lyophilised) powder; it is not a concentration, so a larger vial is not “stronger”, it simply holds more material. Tell us which size you need when you contact us on Telegram or by email.
Handling and research-use notice
Store and handle this material as stated on the label and certificate of analysis for your batch; see our guide to storing research peptides. This product is sold for laboratory research use only. It is not a medicine or supplement and is not for human or veterinary use.
